RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sumitomo Pharma Co Stock

Sumitomo Pharma Co ROCE 2024

Sumitomo Pharma Co ROCE

-1.11

Ticker

4506.T

ISIN

JP3495000006

WKN

858257

In 2024, Sumitomo Pharma Co's return on capital employed (ROCE) was -1.11, a -1,228.35% increase from the 0.1 ROCE in the previous year.

Sumitomo Pharma Co Aktienanalyse

What does Sumitomo Pharma Co do?

Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Sumitomo Pharma Co's Return on Capital Employed (ROCE)

Sumitomo Pharma Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Sumitomo Pharma Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Sumitomo Pharma Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Sumitomo Pharma Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Sumitomo Pharma Co stock

What is the ROCE (Return on Capital Employed) of Sumitomo Pharma Co this year?

The ROCE of Sumitomo Pharma Co is -1.11 undefined this year.

How has the ROCE (Return on Capital Employed) of Sumitomo Pharma Co developed compared to the previous year?

The ROCE of Sumitomo Pharma Co has increased by -1,228.35% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Sumitomo Pharma Co?

A high Return on Capital Employed (ROCE) indicates that Sumitomo Pharma Co has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Sumitomo Pharma Co?

A low ROCE (Return on Capital Employed) can indicate that Sumitomo Pharma Co has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Sumitomo Pharma Co impact the company?

An increase in the ROCE of Sumitomo Pharma Co can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Sumitomo Pharma Co affect the company?

A decrease in ROCE of Sumitomo Pharma Co can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Sumitomo Pharma Co?

Some factors that can affect Sumitomo Pharma Co's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Sumitomo Pharma Co so important for investors?

The ROCE of Sumitomo Pharma Co is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Sumitomo Pharma Co take to improve the ROCE?

To improve the ROCE, Sumitomo Pharma Co can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Sumitomo Pharma Co pay?

Over the past 12 months, Sumitomo Pharma Co paid a dividend of 14 JPY . This corresponds to a dividend yield of about 2.33 %. For the coming 12 months, Sumitomo Pharma Co is expected to pay a dividend of 14 JPY.

What is the dividend yield of Sumitomo Pharma Co?

The current dividend yield of Sumitomo Pharma Co is 2.33 %.

When does Sumitomo Pharma Co pay dividends?

Sumitomo Pharma Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Sumitomo Pharma Co?

Sumitomo Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Sumitomo Pharma Co?

For the upcoming 12 months, dividends amounting to 14 JPY are expected. This corresponds to a dividend yield of 2.33 %.

In which sector is Sumitomo Pharma Co located?

Sumitomo Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sumitomo Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sumitomo Pharma Co from 6/1/2023 amounting to 7 JPY, you needed to have the stock in your portfolio before the ex-date on 3/30/2023.

When did Sumitomo Pharma Co pay the last dividend?

The last dividend was paid out on 6/1/2023.

What was the dividend of Sumitomo Pharma Co in the year 2023?

In the year 2023, Sumitomo Pharma Co distributed 28 JPY as dividends.

In which currency does Sumitomo Pharma Co pay out the dividend?

The dividends of Sumitomo Pharma Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sumitomo Pharma Co

Our stock analysis for Sumitomo Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sumitomo Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.